PATENT CLAIM ANALYSIS

Application Number: 15771941
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "037000"]

Abstract:
This invention concerns the use of mefloquine in relation to  Mycobacterium tuberculosis . This invention also concerns the combination of mefloquine with drugs used in first and second choice treatment of tuberculosis, achieving a reduction in the treatment period of tuberculosis (TB) and the treatment of multi-drug resistant tuberculosis (MDR-TB).

Claim (Index 1):
Pharmaceutical composition characterized by comprising:\n (a) 0.01 p/p of mefloquine; and, (b) 0.01 p/p of at least one, and a maximum of 3, drugs useful in the treatment of tuberculosis, selected from the group consisting of isoniazid, pyrazinamide, rifampicin, ethambutol, streptomycin, ethionamide, aminosalicylic acid, cycloserine, amikacin, kanamycin, capreomycin, linezolid, gatifloxacin, moxifloxacin, sparfloxacin, ofloxacin, ciprofloxacin and levofloxacin; and, (c) Optionally, excipients.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 91.0
- Lexical Diversity: 1.64706
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['10844992', '15546680', '15409911', '14112720', '14816377']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7568324242041535
- 35 USC 102 Novelty (BERT): 0.5066248701486821
- Combined Prediction Score: 0.7318116687986064
- Mean Citation Score: 244.150188
- Max Citation Score: 269.5635
- Similarity Product: 190.5874725428224

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test